ABBVIE

Asciminib (Scemblix) outperformed standard-of-care tyrosine kinase inhibitors in CML, achieving superior major molecular response rates at 96 weeks in the ASC4FIRST trial. The FDA accelerated approval of asciminib was based on 48-week data, and 96-week data further demonstrated its efficacy and safety profile.

Loncastuximab tesirine (Zynlonta) combined with rituximab showed a 97% response rate at 12 weeks in a phase II trial for relapsed or refractory follicular lymphoma, with 67% achieving complete response. The combination demonstrated high progression-free and overall survival rates, suggesting it as a promising treatment option for second-line and later follicular lymphoma.

AbbVie's Emotional Impact Report reveals Black, Hispanic, and Asian CLL patients experience more negative emotional impacts and underutilize support groups. Cultural norms and financial concerns significantly affect their journey, with less effective communication and support from HCPs compared to Caucasian patients. AbbVie aims to address these unmet needs through advocacy collaborations.

In the EXP cohort, median time to response was 2 months, and median time to CR was 5.6 months. Median PFS was 12.8 months, and median OS was not reached (median follow-up 22.8 months). 65% of patients were alive at 15 months. 75% of 12 responders had undetectable MRD. Common non-hematologic TEAEs included CRS (96%), diarrhea (48%), and fatigue (43%). Cytopenias were common, but largely disease-related. Four fatal TEAEs occurred. The OPT cohort showed reduced CRS severity. High response rates were observed in patients with high-risk factors treated with epcoritamab.

The Liquid Handling System Market, valued at USD 4.20 billion in 2023, is projected to reach USD 6.95 billion by 2032, growing at a CAGR of 5.77%. This growth is driven by automation in drug discovery, genomics, and clinical applications, supported by technological advancements and increased demand for precision medicine.

AbbVie announced updated results from the Phase 1b/2 EPCORE NHL-2 trial, showing 96% overall response rate (ORR) and 87% complete response (CR) rate in adult patients with relapsed or refractory follicular lymphoma (FL) treated with epcoritamab + lenalidomide + rituximab (R2). The data highlight the potential benefits of epcoritamab in combination with R2 as a strong and durable treatment option for FL.

AbbVie's Phase 1b/2 EPCORE NHL-2 trial shows 96% overall response rate and 87% complete response rate with epcoritamab plus lenalidomide + rituximab (R2) in relapsed or refractory follicular lymphoma patients, supporting ongoing Phase 3 trial and FDA breakthrough therapy designation.

Epcoritamab (DuoBody® CD3xCD20) + lenalidomide + rituximab (R²) in R/R FL showed 96% ORR and 87% CR rate in a Phase 1b/2 trial with 111 patients, presented at ASH 2024.

AbbVie announced updated results from the Phase 1b/2 EPCORE NHL-2 trial, showing 96% overall response rate (ORR) and 87% complete response (CR) rate in adult patients with relapsed or refractory follicular lymphoma (FL) treated with epcoritamab + lenalidomide + rituximab (R2). The data were presented at the 66th Annual Meeting of the American Society of Hematology (ASH).

AbbVie announced updated results from the Phase 1b/2 EPCORE NHL-2 trial showing 96% overall response rate and 87% complete response rate with epcoritamab + lenalidomide + rituximab in relapsed or refractory follicular lymphoma patients, with 89% of complete responders remaining in CR at 18 months.